Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Current Market Size and Growth Rate of the Precision Oncology Market?
The precision oncology market size has grown rapidly in recent years. It will grow from $95.73 billion in 2024 to $106.21 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to the growing number of companion diagnostics approvals, increasing focus on biomarker discovery and validation, rising investments in oncology research and innovation, increasing number of precision oncology clinical trials, and rising preference for minimally invasive diagnostic techniques.
The precision oncology market size is expected to see rapid growth in the next few years. It will grow to $158.90 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing prevalence of cancer cases, rising adoption of genomics-based diagnostics, growing awareness among patients and clinicians, increasing utilization of next-generation sequencing, and rising demand for targeted cancer therapies. Major trends in the forecast period include advancement in liquid biopsy technologies, advanced use of single-cell sequencing in tumor analysis, development of decentralized testing platforms, innovation in radio genomics for treatment planning, and advancement in patient-specific cancer vaccines.
Claim your free report sample now:
What Are the Key Drivers of the Precision Oncology Market?
The increasing awareness and shift towards personalized therapies are expected to propel the growth of the precision oncology market going forward. Personalized therapies are treatments customized to an individual's genetic makeup, biomarkers, and specific disease characteristics to enhance effectiveness and reduce side effects. Personalized therapies are increasing due to advancements in genomic technologies that enable the precise identification of disease-driving mutations, allowing for more effective and targeted treatments. Precision oncology helps advance personalized therapies by using genomic and molecular profiling to tailor cancer treatment to the specific genetic makeup of a patient's tumor. For instance, in February 2023, according to GOV.UK, a UK-based government department, Health and Social Care Secretary signed an MoU with BioNTech SE to advance cancer vaccine research in England, aiming to deliver 10,000 personalized therapy doses to UK patients by 2030. Therefore, the increasing awareness and shift towards personalized therapies are driving the growth of the precision oncology market.
How Is the Precision Oncology Market Segmented?
The precision oncology market covered in this report is segmented
1) By Type: Genomic Sequencing, Immunotherapy
2) By Product Type: Genetic Tests, Biomarker-Based Tests, Therapeutics
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Skin Cancer, Stomach Cancer, Other Cancers
4) By Technology: Next-Generation Sequencing, Bioinformatics, Molecular Imaging, Liquid Biopsy
5) By End-users: Hospitals, Research Laboratories, Pharmaceutical Companies, Diagnostic Centers
Subsegments:
1) By Genomic Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy
Which Trends Are Positively Affecting the Precision Oncology Market Expansion?
Major companies operating in the precision oncology market are focusing on developing innovative approaches, such as the molecular tumor board, to support personalized treatment decisions by integrating genomic information with clinical context. A molecular tumor board refers to a dedicated panel of specialists that analyzes and interprets complex genomic and molecular test data to inform precision-driven cancer therapies tailored to the specific tumor characteristics of individual patients. For instance, in December 2024, Aster DM Healthcare Ltd., a UAE-based healthcare provider, introduced a precision oncology clinic as part of three personalized cancer care initiatives designed to transform treatment through data-driven, genomic-focused strategies. This clinic delivers customized cancer therapy based on each patient’s tumor genetic profile, enabling more precise, effective treatments with reduced side effects. The approach enhances treatment outcomes, minimizes toxicity, and improves quality of life by aligning therapies to the unique molecular features of a patient's cancer.
Which Are the Top Companies in the Precision Oncology Market?
Major companies operating in the precision oncology market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc., Novartis AG, Eli Lilly and Company, Amgen Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Exact Sciences Corporation, NeoGenomics Laboratories Inc., Myriad Genetics Inc., Invitae Corporation, Caris Life Sciences, Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Strata Oncology Inc.
Get the full precision oncology market report here:
Which Region Is Projected to Account for the Largest Share of the Precision Oncology Market?
North America was the largest region in the precision oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment